Human Longevity

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Solius is a company based in Bainbridge Island, Washington, founded in 2011, that specializes in manufacturing light therapy kiosks aimed at combating vitamin D deficiency. Its innovative device utilizes nano-spectrums of ultraviolet B (UVB) light to stimulate the body's natural production of vitamin D, promoting the synthesis of essential hormones and peptides critical for overall health and well-being. By offering the benefits of sunlight without the harmful UVA rays or the complications associated with vitamin D supplements, Solius enhances physical, mental, and immune functions. The company also developed a UV light system intended for treating COVID-19, further demonstrating its commitment to harnessing light technology for health improvements.

DoctorsForMe, established in 2018 and headquartered in South San Francisco, specializes in AI-driven healthcare solutions. The company connects patients with specific medical needs to suitable healthcare providers, using a vast database of global doctor information to assess expertise and clinical excellence. It operates as a subsidiary of Human Longevity, Inc.

Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting various diseases, including cancer, infectious, and degenerative conditions.

OxStem Limited, incorporated in 2011 and based in Oxford, United Kingdom, focuses on developing cell programming therapies aimed at treating degenerative diseases with significant unmet medical needs. The company intends to create small molecule drugs that activate the body's inherent repair mechanisms. By leveraging extensive experience in medicinal chemistry, OxStem aims to design innovative treatments that can program resident stem and stem-like cells in situ, targeting age-related conditions that are currently untreatable.

Cypher Genomics develops automated software solutions for interpreting human genome data. It serves clinical labs, pharmaceutical companies, and population genomics efforts. Its platform enables tuning sensitivity and specificity profiles to create molecular tests and discover biomarkers. Headquartered in San Diego, California, the company was founded in 2011.